+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Huntington Disease Medications Market - Global Forecast 2026-2032- Product Image
Huntington Disease Medications Market - Global Forecast 2026-2032- Product Image
Sale

Huntington Disease Medications Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6120851
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Huntington Disease Medications Market is projected to reach USD 1.83 Billion in 2026. It is expected to continue growing at a CAGR of 11.29%, reaching USD 3.52 Billion by 2032.

Huntington Disease Medications: Executive Overview

Huntington disease is a hereditary neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric symptoms. Medication management is centered on reducing chorea, addressing mood and behavioral symptoms, supporting sleep and daily functioning, and treating associated complications. Because disease expression and treatment response vary substantially, care typically requires coordination among neurology, psychiatry, rehabilitation, nursing, genetics, and social-support services.

Care Is Shifting Toward Integrated, Patient-Centered Management

The treatment landscape is moving from symptom control alone toward longitudinal, multidisciplinary care. Clinicians increasingly weigh functional status, psychiatric burden, caregiver needs, medication tolerability, and shared decision-making when selecting and adjusting therapies. Greater emphasis on genetic counseling, earlier recognition of symptoms, structured clinical assessment, rehabilitation, and management of comorbidities is also shaping care pathways. Access, affordability, specialist capacity, and continuity of care remain important practical determinants of treatment outcomes.

Artificial Intelligence Is Strengthening Research and Clinical Support

Artificial intelligence may contribute to Huntington disease medication development by helping identify disease-relevant biological signals, analyze imaging and digital biomarkers, and improve trial recruitment and endpoint assessment. In clinical settings, algorithmic tools could support symptom tracking, risk stratification, and personalized monitoring, but their value depends on representative data, transparent validation, privacy safeguards, and clinician oversight. AI should complement-not replace-neurological examination, psychiatric evaluation, patient preferences, and caregiver input.

Regional Insights: Uneven Access and Distinct Care Priorities

North America generally benefits from specialized movement-disorder services, clinical-trial infrastructure, and broader access to advanced diagnostics, although insurance coverage and geographic disparities remain significant. Europe combines strong specialist networks with differences in reimbursement, national guidelines, and cross-border access. Asia-Pacific includes highly developed healthcare systems alongside settings where genetic counseling, specialist diagnosis, and continuity of treatment are limited. Latin America faces uneven specialist distribution, affordability constraints, and underdiagnosis, while public and private capacity varies widely. In the Middle East, concentrated specialist resources coexist with access gaps and the need for culturally appropriate counseling. Africa continues to require stronger diagnostic capacity, referral pathways, caregiver support, and availability of essential symptomatic treatments.

Group Insights: Policy Alignment and Health-System Capacity Matter

ASEAN countries show varied levels of specialist access, genetic services, reimbursement, and research participation, making regional collaboration and workforce development valuable. BRICS members span substantial differences in healthcare infrastructure, regulatory systems, and affordability, with opportunities to strengthen diagnosis and locally relevant evidence. The European Union benefits from coordinated scientific and regulatory initiatives, while national reimbursement and service delivery remain heterogeneous. G7 health systems generally possess strong research and specialist capabilities but still face challenges involving aging populations, caregiver burden, and equitable access. GCC countries have opportunities to expand specialized neurological services and genetic counseling through concentrated healthcare investment. NATO members represent diverse health systems, so continuity of care, military-family support where relevant, and interoperability of clinical standards are important considerations.

Country Insights: Diverse Pathways for Diagnosis and Treatment

Australia has established specialist neurological services but must address geographic dispersion and rural access. Brazil and Mexico continue to face regional inequality in specialist care, diagnosis, and medication availability. Canada and the United States have advanced clinical expertise and research capacity, alongside coverage, affordability, and travel barriers. China and India present major opportunities to expand specialist networks, genetic counseling, and standardized diagnosis across large and diverse populations. Japan and South Korea combine sophisticated healthcare systems with growing needs for coordinated long-term support. France, Germany, Italy, Spain, and the United Kingdom offer substantial neurological expertise, but service organization, reimbursement, and access to specialist multidisciplinary care differ by system. Russia faces the need to strengthen consistent access, diagnostic pathways, and specialist follow-up across its broad geography.

Priorities for Leaders: Improve Access, Evidence, and Continuity of Care

Industry leaders should prioritize therapies and support programs that address clinically meaningful symptoms while maintaining clear evidence on tolerability, functioning, quality of life, and caregiver impact. Partnerships with specialist centers and patient organizations can improve trial engagement, education, and real-world monitoring. Development strategies should incorporate diverse populations, pragmatic endpoints, and transparent patient-reported outcomes. Access planning should consider reimbursement evidence, distribution reliability, genetic counseling, adherence support, and regional workforce limitations. Responsible use of digital and AI-enabled tools requires robust validation, cybersecurity, informed consent, and mechanisms for clinician review.

Research Methodology: Evidence-Based Market Synthesis

This executive summary uses the defined Huntington disease medications market scope and organizes findings across therapeutic care, technology, geography, population groupings, and country systems. Insights are framed from established clinical and health-system considerations rather than unsupported numerical claims. Regional, group, and country observations reflect differences in specialist capacity, diagnostic infrastructure, reimbursement, research participation, and continuity of care. No market estimates, market shares, forecasts, or company-specific claims are included.

Conclusion: Better Outcomes Depend on Coordinated, Equitable Care

Huntington disease medication management is increasingly connected to multidisciplinary services, genetic counseling, rehabilitation, psychiatric care, and sustained caregiver support. The most durable progress will come from combining clinically useful symptom control with earlier diagnosis, stronger evidence generation, responsible digital innovation, and equitable access across diverse health systems. Leaders who align treatment development with patient priorities and real-world care constraints can help improve continuity, safety, and quality of life.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Huntington Disease Medications Market, by Therapy Type
7.1. Introduction
7.2. Disease-Modifying Therapies
7.3. Symptomatic Treatments
7.3.1. Cognitive Symptom Treatments
7.3.1.1. Cholinesterase Inhibitors
7.3.1.2. Nmda Antagonists
7.3.2. Motor Symptom Treatments
7.3.2.1. Antipsychotics
7.3.2.1.1. Olanzapine
7.3.2.1.2. Risperidone
7.3.2.2. Tetrabenazine
7.3.2.3. Vmat2 Inhibitors
7.3.2.3.1. Deutetrabenazine
7.3.2.3.2. Valbenazine
7.3.3. Psychiatric Symptom Treatments
7.3.3.1. Antidepressants
7.3.3.1.1. Ssris
7.3.3.1.1.1. Fluoxetine
7.3.3.1.1.2. Sertraline
7.3.3.1.2. Tcas
7.3.3.2. Antipsychotics
8. Huntington Disease Medications Market, by Mechanism Of Action
8.1. Introduction
8.2. Dopamine Antagonists
8.3. Monoamine Depletors
8.4. Vmat2 Inhibitors
9. Huntington Disease Medications Market, by Distribution Channel
9.1. Introduction
9.2. Offline
9.3. Online
10. Huntington Disease Medications Market, by Formulation
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular
10.2.2. Intravenous
10.3. Oral
10.4. Transdermal
11. Huntington Disease Medications Market, by Patient Age Group
11.1. Introduction
11.2. Adults
11.3. Pediatric
12. Huntington Disease Medications Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Huntington Disease Medications Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Huntington Disease Medications Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Annexon Biosciences, Inc.
16.2. Bausch Health Companies Inc.
16.3. Dr. Reddy's Laboratories Ltd.
16.4. Genentech, Inc.
16.5. H. Lundbeck A/S
16.6. Hikma Pharmaceuticals PLC
16.7. Ionis Pharmaceuticals, Inc.
16.8. Lupin Limited
16.9. Neurocrine Biosciences, Inc.
16.10. Novartis AG
16.11. Pfizer Inc.
16.12. Prilenia Therapeutics, Inc.
16.13. PTC Therapeutics, Inc.
16.14. Roche Holding AG
16.15. Sage Therapeutics, Inc.
16.16. Sun Pharmaceutical Industries Ltd.
16.17. Teva Pharmaceutical Industries Ltd.
16.18. uniQure N.V.
16.19. Voyager Therapeutics, Inc.
16.20. Wave Life Sciences Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Huntington Disease Medications Market, Years Considered for the Study
FIGURE 2. Global Huntington Disease Medications Market, Research Design
FIGURE 3. Global Huntington Disease Medications Market, Research Framework
FIGURE 4. Global Huntington Disease Medications Market, Data Triangulation
FIGURE 5. Global Huntington Disease Medications Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Huntington Disease Medications Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 7. Global Huntington Disease Medications Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Huntington Disease Medications Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 9. Global Huntington Disease Medications Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Huntington Disease Medications Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Huntington Disease Medications Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Huntington Disease Medications Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 13. Global Huntington Disease Medications Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Huntington Disease Medications Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 15. Global Huntington Disease Medications Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Huntington Disease Medications Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Huntington Disease Medications Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Huntington Disease Medications Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Huntington Disease Medications Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Huntington Disease Medications Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Huntington Disease Medications Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Huntington Disease Medications Market Segmentation & Coverage
TABLE 2. Global Huntington Disease Medications Market Size, 2017-2032 (USD Million)
TABLE 3. Global Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 4. Global Disease-Modifying Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Disease-Modifying Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Disease-Modifying Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Symptomatic Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Symptomatic Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Symptomatic Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Cognitive Symptom Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Cognitive Symptom Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Cognitive Symptom Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Cholinesterase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Cholinesterase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Cholinesterase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Nmda Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Nmda Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Nmda Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Motor Symptom Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Motor Symptom Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Motor Symptom Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Antipsychotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Antipsychotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Antipsychotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Olanzapine Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Olanzapine Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Olanzapine Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Risperidone Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Risperidone Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Risperidone Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Tetrabenazine Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Tetrabenazine Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Tetrabenazine Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Vmat2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Vmat2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Vmat2 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Deutetrabenazine Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Deutetrabenazine Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Deutetrabenazine Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Valbenazine Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Valbenazine Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Valbenazine Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Psychiatric Symptom Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Psychiatric Symptom Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Psychiatric Symptom Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Antidepressants Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Antidepressants Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Antidepressants Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Ssris Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Ssris Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Ssris Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Fluoxetine Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Fluoxetine Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Fluoxetine Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Sertraline Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Sertraline Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Sertraline Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Tcas Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Tcas Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Tcas Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Antipsychotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Antipsychotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Antipsychotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 65. Global Dopamine Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Dopamine Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Dopamine Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Monoamine Depletors Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Monoamine Depletors Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Monoamine Depletors Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Vmat2 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Vmat2 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Vmat2 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 75. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 82. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 98. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Huntington Disease Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Huntington Disease Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 120. North America Huntington Disease Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. North America Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 122. North America Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 123. North America Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 124. North America Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 125. North America Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 126. North America Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 127. North America Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 128. North America Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 129. North America Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 130. North America Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 131. North America Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. North America Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 133. North America Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 134. North America Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 135. Latin America Huntington Disease Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Latin America Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 137. Latin America Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 138. Latin America Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 139. Latin America Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 140. Latin America Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 141. Latin America Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 142. Latin America Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 143. Latin America Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 144. Latin America Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 145. Latin America Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 146. Latin America Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. Latin America Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 148. Latin America Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 149. Latin America Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 150. Europe Huntington Disease Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Europe Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 152. Europe Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 153. Europe Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 154. Europe Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 155. Europe Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 156. Europe Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 157. Europe Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 158. Europe Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 159. Europe Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 160. Europe Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 161. Europe Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. Europe Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 163. Europe Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 164. Europe Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 165. Middle East Huntington Disease Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 166. Middle East Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 167. Middle East Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 168. Middle East Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 169. Middle East Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 170. Middle East Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 171. Middle East Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 172. Middle East Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 173. Middle East Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 174. Middle East Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 175. Middle East Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 176. Middle East Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Middle East Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 178. Middle East Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 179. Middle East Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 180. Africa Huntington Disease Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 181. Africa Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 182. Africa Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 183. Africa Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 184. Africa Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 185. Africa Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 186. Africa Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 187. Africa Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 188. Africa Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 189. Africa Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 190. Africa Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 191. Africa Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. Africa Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 193. Africa Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 194. Africa Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 195. Global Huntington Disease Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 196. ASEAN Huntington Disease Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 197. ASEAN Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 198. ASEAN Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 199. ASEAN Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 200. ASEAN Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 201. ASEAN Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 202. ASEAN Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 203. ASEAN Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 204. ASEAN Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 205. ASEAN Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 206. ASEAN Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 207. ASEAN Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. ASEAN Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 209. ASEAN Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 210. ASEAN Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 211. GCC Huntington Disease Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. GCC Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 213. GCC Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 214. GCC Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 215. GCC Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 216. GCC Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 217. GCC Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 218. GCC Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 219. GCC Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 220. GCC Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 221. GCC Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 222. GCC Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. GCC Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 224. GCC Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 225. GCC Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 226. European Union Huntington Disease Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 227. European Union Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 228. European Union Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 229. European Union Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 230. European Union Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 231. European Union Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 232. European Union Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 233. European Union Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 234. European Union Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 235. European Union Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 236. European Union Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 237. European Union Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. European Union Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 239. European Union Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 240. European Union Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 241. BRICS Huntington Disease Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 242. BRICS Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 243. BRICS Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 244. BRICS Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 245. BRICS Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 246. BRICS Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 247. BRICS Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 248. BRICS Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 249. BRICS Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 250. BRICS Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 251. BRICS Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 252. BRICS Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 253. BRICS Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 254. BRICS Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 255. BRICS Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 256. G7 Huntington Disease Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 257. G7 Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 258. G7 Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 259. G7 Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 260. G7 Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 261. G7 Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 262. G7 Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 263. G7 Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 264. G7 Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 265. G7 Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 266. G7 Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 267. G7 Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. G7 Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 269. G7 Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 270. G7 Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 271. NATO Huntington Disease Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 272. NATO Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 273. NATO Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 274. NATO Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 275. NATO Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 276. NATO Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 277. NATO Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 278. NATO Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 279. NATO Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 280. NATO Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 281. NATO Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 282. NATO Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 283. NATO Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 284. NATO Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 285. NATO Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 286. Global Huntington Disease Medications Market Size, by Country, 2017-2032 (USD Million)
TABLE 287. United States Huntington Disease Medications Market Size, 2017-2032 (USD Million)
TABLE 288. United States Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 289. United States Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 290. United States Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 291. United States Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 292. United States Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 293. United States Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 294. United States Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 295. United States Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 296. United States Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 297. United States Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 298. United States Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. United States Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 300. United States Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 301. United States Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 302. Canada Huntington Disease Medications Market Size, 2017-2032 (USD Million)
TABLE 303. Canada Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 304. Canada Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 305. Canada Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 306. Canada Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 307. Canada Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 308. Canada Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 309. Canada Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 310. Canada Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 311. Canada Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 312. Canada Huntington Disease Medications Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 313. Canada Huntington Disease Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 314. Canada Huntington Disease Medications Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 315. Canada Huntington Disease Medications Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 316. Canada Huntington Disease Medications Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 317. Mexico Huntington Disease Medications Market Size, 2017-2032 (USD Million)
TABLE 318. Mexico Huntington Disease Medications Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 319. Mexico Huntington Disease Medications Market Size, by Symptomatic Treatments, 2017-2032 (USD Million)
TABLE 320. Mexico Huntington Disease Medications Market Size, by Cognitive Symptom Treatments, 2017-2032 (USD Million)
TABLE 321. Mexico Huntington Disease Medications Market Size, by Motor Symptom Treatments, 2017-2032 (USD Million)
TABLE 322. Mexico Huntington Disease Medications Market Size, by Antipsychotics, 2017-2032 (USD Million)
TABLE 323. Mexico Huntington Disease Medications Market Size, by Vmat2 Inhibitors, 2017-2032 (USD Million)
TABLE 324. Mexico Huntington Disease Medications Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 325. Mexico Huntington Disease Medications Market Size, by Antidepressants, 2017-2032 (USD Million)
TABLE 326. Mexico Huntington Disease Medications Market Size, by Ssris, 2017-2032 (USD Million)
TABLE 327. Mexico

Companies Mentioned

  • Annexon Biosciences, Inc.
  • Bausch Health Companies Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Genentech, Inc.
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Ionis Pharmaceuticals, Inc.
  • Lupin Limited
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Prilenia Therapeutics, Inc.
  • PTC Therapeutics, Inc.
  • Roche Holding AG
  • Sage Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • uniQure N.V.
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.

Related Topics

Related Reports

Huntington's Disease Treatment Market Report 2026 - Product Image

Huntington's Disease Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Huntington's Disease - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Huntington's Disease - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 198 Pages
  • Global
From
VMAT2 Inhibitor Market - Global Forecast 2026-2032 - Product Image

VMAT2 Inhibitor Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Huntington`s Disease Therapeutics Market - Global Forecast 2026-2032 - Product Image

Huntington`s Disease Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Huntington's Disease Treatment Market Size, Share, Trends and Forecast by Type, Drug Type, Age, Distribution Channel, End User, and Region, 2026-2034 - Product Image

Huntington's Disease Treatment Market Size, Share, Trends and Forecast by Type, Drug Type, Age, Distribution Channel, End User, and Region, 2026-2034

  • Report
  • 142 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.